# Niki BioSolutions Subsidiary Featured in Rett Syndrome Research Series

- URL: https://stocks.freetheai.org/news/niki-biosolutions-subsidiary-featured-in-rett-syndrome-research-series-f4ff00
- Published: 2026-10-16T12:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:NIKI](https://stocks.freetheai.org/symbols/NASDAQ-NIKI)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Niki BioSolutions, Inc. (NIKI) announced that its subsidiary, DiamiR Biosciences Corp., was selected for inclusion in the International Rett Syndrome Foundation's research series highlighting key technologies in disease research. Shares of the company rose 3.49% to $2.22 following the announcement.

The company is developing a 44-microRNA blood panel to track disease severity and therapeutic response in Rett syndrome patients. The panel was previously evaluated in blood samples from more than 200 individuals in clinical studies conducted alongside Montefiore Medical Center and Albert Einstein College of Medicine. Objective, minimally invasive biomarkers can help researchers and clinicians better evaluate treatments and guide patient care during drug development.

Investors and researchers will monitor how Niki BioSolutions advances its microRNA testing platform into broader clinical research and potential biopharma partnerships. Further validation and potential adoption in clinical trials will be key indicators of the program's progress.

## Key points

- DiamiR Biosciences was featured in the International Rett Syndrome Foundation research series.
- The company is developing a 44-microRNA panel to monitor Rett syndrome severity and treatment response.
- The blood-based biomarker test was evaluated in over 200 individuals across two clinical studies.
- Shares of Niki BioSolutions, Inc. (NIKI) gained 3.49% to trade at $2.22.

## Questions and answers

### What is Niki BioSolutions developing for Rett syndrome?

Niki BioSolutions is developing a blood-based biomarker panel made of 44 organ-enriched microRNAs to help monitor disease progression, severity, and response to treatment in Rett syndrome patients.

### How was Niki BioSolutions' Rett syndrome biomarker panel tested?

The biomarker panel was evaluated using blood samples from over 200 individuals with and without Rett syndrome in two clinical studies in partnership with Montefiore Medical Center and Albert Einstein College of Medicine.

### Why was Niki BioSolutions featured by the International Rett Syndrome Foundation?

Its subsidiary, DiamiR Biosciences, was selected for the foundation's research series, which highlights technologies that advance Rett syndrome research and clinical drug development.